Acta Pharmaceutica Sinica B
|
2026, 16(4): 2232-2249
• REVIEW •
Advances of microneedle technology for the treatment of autoimmune diseases
Full
Ying Chen1, Yanping Fu1, Xinyu Wen1, Minglong Chen2, Linghui Dian3, Tingting Peng1, Chuanbin Wu1,4, Chao Lu1, Guilan Quan1
Affiliations
1 State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou 511443, China;
2 CAS Key Laboratory of Soft Matter Chemistry, Department of Polymer Science and Engineering, University of Science and Technology of China, Hefei 230026, China;
3 College of Pharmacy, Guangdong Medical University, Dongguan 523808, China;
4 Jiangmen Wuyi Hospital of Traditional Chinese Medicine, Affiliated Jiangmen Traditional Chinese Medicine Hospital of Jinan University, Jiangmen 529031, China
doi: 10.1016/j.apsb.2026.01.003
Outline
Autoimmune diseases are characterized by an aberrant immune response directed against the body's own components, leading to immune dysfunction and loss of tolerance. This ultimately results in tissue damage and organ impairment. Despite the availability of a range of pharmacological agents for the treatment of autoimmune diseases, numerous challenges still remain. These include reduced bioavailability, first-pass metabolism, severe adverse effects, and low patient compliance associated with oral or injectable routes of administration. Microneedles (MNs) based delivery systems offer a promising alternative for transdermal drug administration, as they can circumvent the aforementioned limitations via the generation of microchannels in the skin in a minimally invasive manner with low pain. This review examines the applications and recent advances in MN systems for treating autoimmune diseases, focusing on six key areas: an overview of autoimmune diseases, current treatment modalities, an introduction to MNs, advantages of MNs for autoimmune disease treatment, advancements in MN-mediated therapies for diverse autoimmune diseases, and relevant MN technologies currently undergoing clinical trials. Additionally, it considers the prospective future advancements of MN systems in the management of autoimmune diseases.
Microneedle
/
Autoimmune diseases
/
Transdermal drug delivery system
/
Clinical trials
/
Immunomodulation
/
Targeted therapy
/
Treatment innovations
/
Skin penetration
Ying Chen, Yanping Fu, Xinyu Wen, Minglong Chen, Linghui Dian, Tingting Peng, Chuanbin Wu, Chao Lu, Guilan Quan.
Advances of microneedle technology for the treatment of autoimmune diseases[J].
Acta Pharmaceutica Sinica B,
2026
, 16
(4)
: 2232
-2249
.
DOI: 10.1016/j.apsb.2026.01.003
Year 2026 volume 16 Issue 4
PDF
7
4
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.apsb.2026.01.003
- Receive Date:2025-01-28
- Online Date:2026-09-17